Leaders in Diagnostic Innovation
Transforming Healthcare with Point-of-Care Solutions
We distribute cutting-edge diagnostic tools such as FebriDx®, empowering healthcare providers with rapid, reliable results.
Our mission is to reduce unnecessary treatments and improve patient care by providing precision diagnostic solutions.
Bacterial or non-bacterial infection?
FebriDx® aids in the differentiation between bacterial infection and non-bacterial etiology.
Acute respiratory infections, such as sore throat, cough, and congestion, are the most common reasons for seeking medical advice. Distinguishing between bacterial and non-bacterial infections can be challenging, with antibiotics often unnecessarily prescribed in up to 50% of cases. Antibiotic resistance remains a significant global health issue, contributing to over 2.8 million resistant infections and 35,000 deaths annually. In the U.S. The estimated national cost to treat infections caused by six antimicrobial-resistant germs frequently found in health care can be substantial—more than $4.6 billion annually
1-3
4
5
6
Results after 10 Minutes from Fingerstick
FebriDx delivers results after 10 minutes, from fingerstick. This allows the healthcare providers to quickly determine whether a bacterial infection is present and make timely decisions about antibiotic prescriptions.
9
Combatting a Global Health Threat
Antibiotic resistance contributes to 2.8 million illnesses and 35,000 deaths annually in the U.S. FebriDx aids in the fight against this threat by accurately identifying bacterial infections, limiting unnecessary antibiotic prescriptions.
8
5
Targets Antibiotic Overuse
With up to 50% of acute respiratory infections currently treated with antibiotics unnecessarily, FebriDx helps reduce the inappropriate use of antibiotics, directly addressing a major contributor to antibiotic resistance.
7
Portable, All-in-One Solution
FebriDx is an instrument-free, point-of-care test that uses a simple fingerstick blood sample, making it a fully portable and cost-effective solution for urgent and emergency care settings.
We offer full-spectrum support to help healthcare providers maximize the potential of FebriDx® and our other diagnostic solutions.
Our Comprehensive Provider Support
Enabling Providers to Focus on What Matters Most - Their Patients
Provider Training​
From implementation to ongoing training, we equip your team with the knowledge and skills to seamlessly integrate our products into your practice.​
Clinical Guidance​
We provide clinical insights and on-demand resources to help you optimize patient outcomes.
Onboarding and Ordering Support​
Our team guides you through the onboarding process from ordering to reimbursement, ensuring easy and efficient access to diagnostic tools.
​1) Harris AM, Hicks LA, Qaseem A. Appropriate antibiotic use for acute respiratory tract infection in adults: advice for high-value care from the American College of Physicians and the Centers for Disease Control and Prevention. Ann Intern Med. 2016;164(6):425-434.
​
2) Centers for Disease Control and Prevention (CDC). National Ambulatory Medical Care Survey. National Center for Health Statistics. Updated December 30, 2021. Accessed Jan, 2024, https://www.cdc.gov/nchs/ahcd/about_ahcd.htm
​
3) Renati S, Linder JA. Necessity of office visits for acute respiratory infections in primary care. Fam Pract. 2016;33(3):312-317.
​
4) Centers for Disease Control and Prevention (CDC). Measuring Outpatient Antibiotic Prescribing. Updated Oct 2022. Accessed Feb 2024, https://www.cdc.gov/antibiotic-use/data/outpatient-prescribing/index.html
​
5) Centers for Disease Control and Prevention (CDC). Antibiotic Resistance Threats in the United States, 2019. U.S. Department of Health and Human Services. Updated Dec 2019. Accessed Jan 2024, https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report-508.pdf
6) Richard E Nelson, Kelly M Hatfield, Hannah Wolford, Matthew H Samore, R Douglas Scott, Sujan C Reddy, Babatunde Olubajo, Prabasaj Paul, John A Jernigan, James Baggs, National Estimates of Healthcare Costs Associated With Multidrug-Resistant Bacterial Infections Among Hospitalized Patients in the United States, Clinical Infectious Diseases, Volume 72, Issue Supplement_1, 15 January 2021, Pages S17–S26, https://doi.org/10.1093/cid/ciaa158​​
​
7) Shapiro NI, Self WH, Rosen J, et al. A prospective, multi-centre US clinical trial to determine accuracy of FebriDx point-of-care testing for acute upper respiratory infections with and without a confirmed fever. Ann Med. Aug 2018;50(5):420-429. doi:10.1080/07853890.2018.1474002
​
8) Shapiro NI, Filbin MR, Hou PC, et al. Diagnostic Accuracy of a Bacterial and Viral Biomarker Point-of-Care Test in the Outpatient Setting. JAMA Netw Open. Oct 3 2022;5(10):e2234588. doi:10.1001/jamanetworkopen.2022.34588
​
9) Carlton HC, Savović J, Dawson S, Mitchelmore PJ, Elwenspoek MM. Novel point-of-care biomarker combination tests to differentiate acute bacterial from viral respiratory tract infections to guide antibiotic prescribing: A systematic review. Clinical Microbiology and Infection. 2021
Reach Out for Support
Your Partner in Precision Diagnostics
Have questions about FebriDx or our other diagnostic products? Contact us for personalized assistance.
Contact Us Today